<DOC>
	<DOCNO>NCT00002609</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver tumor-killing substance , without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy monoclonal antibody therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness chemotherapy plus monoclonal antibody therapy treat patient acute promyelocytic leukemia remission .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy Chemotherapy Treating Patients With Acute Promyelocytic Leukemia Remission</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate antileukemic effect humanize anti-CD33 monoclonal antibody M195 ( HuM195 ) minimal residual disease patient acute promyelocytic leukemia ( APL ) use reverse transcription-polymerase chain reaction mutate retinoic acid receptor-alpha detect change minimal residual disease . II . Assess disease free overall survival patient APL receive HuM195 minimal residual disease . III . Evaluate safety toxicity HuM195 patient . IV . Evaluate whether HuM195 elicit human anti-human antibody response , include anti-idiotype antibody response , patient APL . OUTLINE : Patients continue retinoid therapy 30 day documentation clinical complete remission . Patients begin treatment within 10 day documentation clinical complete remission , RT-PCR-confirmed molecular relapse , 3-6 week chemotherapy . Patients receive HuM195 IV 60 minute twice week 6 dos . Patients unacceptable toxicity , first complete remission , ineligible bone marrow transplant ( BMT ) proceed next regimen . Patients receive idarubicin IV 15 minute day 1-3 cytarabine IV continuously day 1-5 . Patients receive 2 course , give 4-6 week interval , consist idarubicin IV 15 minute day 1-2 cytarabine IV continuously day 1-4 . Patients begin maintenance therapy toxicity resolve 1 week last dose HuM195 . This consist HuM195 IV 60 minute 2 dos ( 72-96 hour apart ) . Treatment repeat month 6 course . Patients initial molecular response positive RT-PCR assay , achieve complete remission follow clinical relapse disease treatment eligible retreatment . Patients follow every 3 month . PROJECTED ACCRUAL : A total 14-40 patient accrue study 2-3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm acute promyelocytic leukemia one follow category : First complete remission follow induction retinoids First complete remission follow induction chemotherapy eligible additional consolidation chemotherapy Second subsequent remission follow induction retinoids chemotherapy Clinically complete remission follow consolidation chemotherapy : Detectable minimal residual disease reverse transcriptionpolymerase chain reaction ( RTPCR ) assay Not eligible bone marrow transplant Molecular remission ( i.e. , negative RTPCR assay ) subsequent evidence early molecular relapse ( i.e. , normal peripheral blood count , normal bone marrow morphology , positive RTPCR assay ) PATIENT CHARACTERISTICS : Age : 12 Performance status : Not specify Life expectancy : Greater 4 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.5 mg/dL AST great 4 time normal Alkaline phosphatase great 4 time normal Renal : Creatinine great 2.5 mg/dL Cardiovascular : ( Patients receive idarubicin cytarabine ) No history cardiac disease OR Left ventricular ejection fraction great 50 % MUGA echocardiogram Other : No uncontrolled serious infection HIV negative No active second malignancy except basal cell carcinoma Not pregnant nursing Negative pregnancy test Fertile woman must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : See Disease Characteristics Retinoid therapy continue 30 day past complete remission No concurrent chemotherapy At least 3 week since cytotoxic chemotherapy recover Endocrine therapy : Not specify Radiotherapy : At least 3 week since radiotherapy recover No concurrent radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
</DOC>